Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial Biotech Investing
Menlo Therapeutics Inc. Announces Pricing of Initial Public Offering of Common Stock Biotech Investing
Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split Pharmaceutical Investing
Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018 Life Science Investing
MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis Biotech Investing
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Life Science Investing
